TEAM CLASSIC

CONSTRAT CASE STUDY

CASE : ANTI SMOKING

PILLS

TEAM MEMBERS :

ALOK RANJAN
DEEPAM GUPTA
LAKSHITA UPPAL
SIDDESH GANESH
 TOPICS TO BE COVERED
The product characteristics (development and customization) for the Indian
market.
The competition which can be faced by the company.
How the product is to be launched (distribution and promotion) in the Indian
market.
A daily cigarette smoker in India spends Rs 1,192.45 per month on
average manufactured cigarettes
Categorized of smoking
cessation and nicotine de-
addiction market
Three major segments including

Drug therapy

Nicotine Replacement Therapy (NRT)

The NRT segment comprises sprays, inhalers, chewing
gums, transdermal patches, lozenges, and sublingual
tablets. This segment held the largest market share in
2015 with revenue of over USD 3,000million owing to its
ease of use, its increased accessibility, and its
effectiveness in reducing the nicotine craving in smokers.

Electronic cigarettes (E-cigarettes)

Age at the initiation of
tobacco use in India:
The age at the initiation of tobacco use either in
smoking or smokeless form is an important
dimension since it determines the duration of
tobacco use. The duration of tobacco use has a
direct effect on the health impact due to tobacco.
 Competition in anti-smoking
medicine segment
Varenicline
Varenicline, a non-nicotine based drug that has
been proven to be effective in assisting smoking
cessation is marketed as Chantix in the U.S and
Champixin other parts of the globe.
 Zyban
Zyban is another widely used drug, used in
combination with NRT for effective results.
Nicorette Buccal
 Some key players of the smoking
cessation and nicotine de-addiction
market
Pfizer, Inc., Cipla Ltd., Novartis International AG, GlaxoSmithKline plc, Takeda pharmaceutical
Company Ltd., McNeil AB, Revolymer plc, Imperial Tobacco Ltd., and VMR products, LLC
THANK YOU